- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00634491
Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy
March 4, 2008 updated by: Shiraz University of Medical Sciences
Effect of Acetazolamide in Prevention of Contrast Nephropathy
The purpose of this study is whether Acetazolamide is effective in prevention of contrast nephropathy
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Contrast induced nephropathy is one of common causes of acute renal failure many preventive protocol existed .
240 patient that underwent coronary angiography randomly divided in three groups.Group 1,2,3 will receive Bicarbonate ,Acetazolamide+Normal salin and Normal salin respectively.We compare prevalence of contrast nephropathy in each group.
Study Type
Interventional
Enrollment (Actual)
240
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shiraz, Iran, Islamic Republic of
- Fars Heart Foundation , Kowsar hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patient that underwent coronary angiography
Exclusion Criteria:
- serum Cr. more than 3 mg/dl
- electrolyte and acid-base imbalance
- pulmonary edema
- allergy to Acetazolamide
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: 1
150 meq/l NaHco3 3cc/kg/hr one Hour before and 1cc/kg/hr 6 hour after angiography
|
150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
Other Names:
|
|
Active Comparator: 2
Acetazolamide 250 mg + 1cc/kg/hr normal salin 6 hour before and after angiography
|
Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
Other Names:
|
|
Active Comparator: 3
normal salin 1cc/kg/hr before and after angiography
|
1 cc/kg/hr 6 hour before and after angiography
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Increased base line creatinine at least 25%
Time Frame: 24 hr later
|
24 hr later
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Maryam Pakfetrat, MD, Shiraz nephro-urology research center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2007
Primary Completion (Actual)
February 1, 2008
Study Completion (Actual)
February 1, 2008
Study Registration Dates
First Submitted
February 14, 2008
First Submitted That Met QC Criteria
March 4, 2008
First Posted (Estimate)
March 13, 2008
Study Record Updates
Last Update Posted (Estimate)
March 13, 2008
Last Update Submitted That Met QC Criteria
March 4, 2008
Last Verified
March 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2438
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contrast Induced Nephropathy
-
Minia UniversityNot yet recruitingContrast-induced Nephropathy
-
Gaziosmanpasa Research and Education HospitalRecruitingContrast-induced Nephropathy | Contrast-Associated Acute Kidney InjuryTurkey (Türkiye)
-
Singapore General HospitalActive, not recruitingContrast-induced NephropathySingapore
-
Chinese PLA General HospitalUnknownContrast-induced NephropathyChina
-
Memorial University of NewfoundlandUniversity of AlbertaWithdrawnContrast Induced NephropathyCanada
-
Sun Yat-sen UniversityCompletedContrast Induced NephropathyChina
-
Isfahan University of Medical SciencesUnknownContrast-Induced NephropathyIran, Islamic Republic of
-
Osprey Medical, IncCompletedContrast Induced Nephropathy (CIN)United States, New Zealand, Australia
-
The Nazareth HospitalWestern Galilee Hospital-NahariyaUnknownContrast Media Induced NephropathyIsrael
-
Mt. Sinai Medical Center, MiamiFlorida Heart Research InstituteCompleted
Clinical Trials on sodium bicarbonate
-
Sheba Medical CenterUnknownExtravasation | InfiltrationIsrael
-
HALEONCompletedGingivitisUnited Kingdom
-
GlaxoSmithKlineCompleted
-
Guy's and St Thomas' NHS Foundation TrustUniversity of PittsburghActive, not recruiting
-
Jennifer Gassman, PhDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The...CompletedChronic Kidney DiseaseUnited States
-
Wake Forest University Health SciencesCompletedRenal Replacement Therapy | Kidney Failure, AcuteUnited States
-
University of UtahThe University of Utah Center on AgingTerminatedChronic Kidney DiseaseUnited States
-
Kaiser PermanenteCompletedKidney Diseases | Contrast Induced NephropathyUnited States
-
Instituto Nacional de Cardiologia Ignacio ChavezUnknownAcute Kidney FailureMexico
-
Prim. Priv. Doz. Dr. Daniel CejkaMedice Arzneimittel Pütter GmbH & Co KGWithdrawnKidney Transplant; ComplicationsAustria